Objective:

To report the FDA approval of Auvelity for treating agitation associated with Alzheimer's disease.

Approach:

Key Findings:

• Agitation affects up to 76% of Alzheimer's patients.
• Dextromethorphan-bupropion significantly improved agitation symptoms in clinical trials.
• The treatment has a specific dosing regimen for agitation in Alzheimer's, differing from major depressive disorder.

Interpretation:

The approval of Auvelity provides a new treatment option for managing agitation in Alzheimer's patients, addressing a significant symptom that affects quality of life.

Limitations:

• The mechanism of action for agitation treatment remains unclear.
• The relapse findings in ACCORD-2 should be interpreted with caution due to prior responder enrollment.

Conclusion:

Auvelity's approval represents a significant advancement in the treatment of agitation in Alzheimer's disease, with specific dosing and safety considerations.

Sources:

• Axsome Therapeutics Press Release
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.